Nature Search

Evaluation of mortality attributable to SARS-CoV-2 vaccine administration using national level data from Qatar

This study assesses the probability that deaths following a COVID-19 vaccination are attributable to the vaccine. The authors review all deaths that occurred within 30 days of vaccine receipt in Qatar until June 2022 and find that deaths attributable to vaccination are extremely rare.

Adeel A. Butt
Mylai D. Guerrero
Abdul-Badi Abou-Samra
ResearchOpen Access03 Jan 2023
Nature Communications

Volume: 14, P: 1-5
Effectiveness and durability of a fourth dose of ancestral-strain mRNA vaccines against SARS-CoV-2 infection: a nationwide matched cohort study in Qatar

Layan Sukik
Hiam Chemaitelly
Laith J. Abu-Raddad
ResearchOpen Access08 Oct 2025
Scientific Reports

Volume: 15, P: 1-11
Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications

Prognostic markers for patients with COVID-19 are of critical importance in determining the course of SARS-CoV-2 infection and patient handling. Here the authors determine and apply a prognostic proteomic panel for risk and drug prediction in the management of SARS-CoV-2 infected patients.

Maryam A. Y. Al-Nesf
Houari B. Abdesselem
Fares Al-Ejeh
ResearchOpen Access17 Feb 2022
Nature Communications

Volume: 13, P: 1-14
Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron

Two distinct patterns in the protective effect of natural infection against reinfection in the Omicron variant versus pre-Omicron eras show that SARS-CoV-2 immune protection is shaped by dynamic interaction between host immunity and viral evolution.

Hiam Chemaitelly
Houssein H. Ayoub
Laith J. Abu-Raddad
ResearchOpen Access05 Feb 2025
Nature

Volume: 639, P: 1024-1031
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

The SARS-CoV-2 Omicron variant has subvariants with divergent properties but relative vaccine effectiveness has not been characterized. Here, the authors show that mRNA vaccine effectiveness is similar for the subvariants BA.1 and BA.2, with a decline three months after the second dose and increase after the booster.

Hiam Chemaitelly
Houssein H. Ayoub
Laith J. Abu-Raddad
ResearchOpen Access02 Jun 2022
Nature Communications

Volume: 13, P: 1-12
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

mRNA COVID-19 vaccines are highly effective at preventing severe outcomes and death caused by the SARS-CoV-2 Delta variant (B.1.617.2) in Qatar despite substantially lower effectiveness at blocking infection.

Patrick Tang
Mohammad R. Hasan
Laith J. Abu-Raddad
Research02 Nov 2021
Nature Medicine

Volume: 27, P: 2136-2143
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

A matched test-negative, case-control study using real-world data from a predominantly working-age population demonstrates efficacy of the mRNA-1273 vaccine to be 100% and 96.4% against the B.1.1.7 (Alpha) and B.1.351 (Beta) SARS-CoV-2 variants of concern, respectively.

Hiam Chemaitelly
Hadi M. Yassine
Laith J. Abu-Raddad
Research09 Jul 2021
Nature Medicine

Volume: 27, P: 1614-1621
Molecular characteristics of Neisseria meningitidis in Qatar

Manal Mahmoud Hamed
Fayaz Ahmad Mir
Sanjay H. Doiphode
ResearchOpen Access26 Feb 2021
Scientific Reports

Volume: 11, P: 1-7
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

The level of immunity induced by infection with different SARS-CoV-2 Omicron sub-lineages against infection with other sub-lineages is not known. Here, the authors use data from Qatar and show that infection with BA.1 induces strong protection against infection with BA.2, and vice versa, for several weeks.

Hiam Chemaitelly
Houssein H. Ayoub
Laith J. Abu-Raddad
ResearchOpen Access09 Aug 2022
Nature Communications

Volume: 13, P: 1-11
Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections

SARS-CoV-2 breakthrough infections in vaccinated individuals and reinfections in those with prior infection are a public health concern. Here, the authors show that viral loads of vaccine breakthrough infections and reinfections are generally lower than primary infections of unvaccinated individuals, potentially indicating lower infectiousness.

Laith J. Abu-Raddad
Hiam Chemaitelly
Roberto Bertollini
ResearchOpen Access27 Jan 2022
Nature Communications

Volume: 13, P: 1-11
Immune histories and natural infection protection during the omicron era

Chemaitelly et al. investigate effects of immune history on SARS-CoV-2 reinfections using three retrospective cohort studies in Qatar from 28 February 2020 to 12 August 2024. Two sequential omicron infections after vaccination offer less protection than a single omicron infection occurring either after vaccination alone or following a pre-omicron infection and vaccination.

Hiam Chemaitelly
Houssein H. Ayoub
Laith J. Abu-Raddad
ResearchOpen Access01 Jul 2025
Communications Medicine

Volume: 5, P: 1-10
Prevalence of hepatitis B and C viruses among migrant workers in Qatar

Gheyath K. Nasrallah
Hiam Chemaitelly
Laith J. Abu-Raddad
ResearchOpen Access17 May 2024
Scientific Reports

Volume: 14, P: 1-11
SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar

Shaheen Seedat
Hiam Chemaitelly
Laith J. Abu-Raddad
ResearchOpen Access14 Sept 2021
Scientific Reports

Volume: 11, P: 1-10
Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population

Gheyath K. Nasrallah
Soha R. Dargham
Laith J. Abu-Raddad
ResearchOpen Access04 Jun 2021
Scientific Reports

Volume: 11, P: 1-10
Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic

Laith J. Abu-Raddad
Hiam Chemaitelly
Roberto Bertollini
ResearchOpen Access18 Mar 2021
Scientific Reports

Volume: 11, P: 1-15

Search

Evaluation of mortality attributable to SARS-CoV-2 vaccine administration using national level data from Qatar

Effectiveness and durability of a fourth dose of ancestral-strain mRNA vaccines against SARS-CoV-2 infection: a nationwide matched cohort study in Qatar

Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications

Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Molecular characteristics of Neisseria meningitidis in Qatar

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections

Immune histories and natural infection protection during the omicron era

Prevalence of hepatitis B and C viruses among migrant workers in Qatar

SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar

Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population

Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic

Search

Quick links

Search

Filter By:

Search

Quick links